A new study suggests that how parents talk to children may matter just as much as how much time they spend talking.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients
Shares of Gemphire Therapeutics crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease treatment for pediatric patients actually worsened the disease in some patients.
Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.
Low-calorie sweetened beverages such as diet sodas that use aspartame or stevia may be a good replacement for full-sugar sodas and fruit juices, but researchers are still unsure about their long-term health effects, according to a new American Heart Association Science Advisory.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Bellerophon Therapeutics’ Phase III pulmonary arterial hypertension drug INOpulse failed to meet endpoints following a pre-specified interim analysis from a Data Monitoring Committee.
An investigational gene therapy treatment for hemophilia A saw a 97 percent response rate after one treatment.
Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significantly
Ovid Therapeutics reported that the Phase II STARS trial of OV101 for Angelman Syndrome showed “robust and statistically significant improvement,” but the company’s stock plunged nearly 30 percent in premarket trading.
Scientists with Framingham, Mass.-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid (Aβ), the primary driver of Alzheimer’s disease.